Hitchhiking cancer vaccine makes progress in clinic miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
ELI-002, a vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, is showing promising early study results but potential commercial availability of the drug is likely several years away as one researcher tells CURE®.
Published data shows lymph node-targeted Amphiphile -peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors.
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses.
BOSTON, Jan. 16, 2024 Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert.